Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Low Carbohydrate Diet in Diabetic Kidney Disease

10 juni 2021 uppdaterad av: Rohana Abdul Ghani, Universiti Teknologi Mara

Effects of Low Carbohydrate Diet (LCBD) on Weight and Renal Outcome in Patients With Diabetic Kidney Disease (DKD)- A Pilot Study

The current population of type 2 diabetes mellitus (T2DM) worldwide is over 200 million and Malaysia contributes to 1.2% of that number. The prevalence of T2DM in Malaysia has approximately tripled over the last three decades from 6.3% in 1986 to 17.5% of the adult population in 2015.T2DM is a progressive disease associated with debilitating microvascular and macrovascular complications. The prevalence of chronic kidney disease (CKD) in Peninsular Malaysia was high at 9.1% of the adult population in 2011. T2DM is the leading cause of renal failure for patients commencing dialysis, increasing from 53% of new dialysis patients in 2004 to 61% in 2013. Therefore, diabetic kidney disease (DKD) is a debilitating complication which not only imposes significant health problems but also confers financial burden on affected patients. There has been increasing amount of understanding in the complexity of the relationship between T2DM and obesity. As the prevalence of both conditions continue to demonstrate a parallel rise, the influence of obesity on T2DM is further marked. Thus, this has led to greater emphasis on weight loss in the management of T2DM. More recent anti-diabetic medications including SGLT-2 inhibitors and GLP1 agonists demonstrated greater efficacy in improving glycaemic control and their ability to produce weight reduction. In addition, there has been more interest in the effects of these drugs on retardation of renal disease progression. The mechanism is unclear, either attributed by direct drug effects on renal glomerular-tubular structures, through the Renin-Angiotensin-Aldosterone-System (RAAS), or other pathways. Another pausible explanation is the significant weight loss, which has been shown to have a significant effect of attenuation of renal disease.

Weight reduction programs have long been a complex and tedious treatment plan which has inconsistent, non-duplicable and unpredictable outcomes. Most programs emphasized on medical nutrition therapy and lifestyle changes. There has been many different dietary plans which share a common goal ie to reduce calori intake whilst increasing energy expenditure. Few have been successfully reproducible, limited by either patient adherence or modest outcome.

Low carbohydrate diet is a diet plan which stresses on reducing carbohydrate intake to less than 20g daily. Numerous studies have shown that weight loss could be obtained by reduction of calori intake in either the form of carbohydrate or fat. CKD patients are recommended to consume low protein diet of less than 0.6-0.7g/kg/day with little emphasis on calori or carbohydrate intake.

This study, thus, aims to evaluate the effects of low carbohydrate and moderate fat (LCBD) in addition to low protein diet on renal disease in patients with DKD.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

This is an investigator-initiated, single center, randomized, controlled, clinical trial in Type 2 diabetes mellitus patients, comparing 16-weeks of LCBD compared to standard medical therapy in patients with DKD.

Patients would be recruited from the Endocrinology and Nephrology clinics in UiTM Medical Specialist Center. Inclusion criteria would include patients aged between 40-75 years old, diagnosis with Type 2 DM of more than 5 years with stable CKD stage 2 and 3 of more than 6 months, HbA1c of 7% - 10.5%.

Exclusion Criteria include patients with Type 1 DM, experiencing frequent hypoglycaemia, abnormal liver function tests, heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease, malignancy, recent hospital admission within the past 3 months, pregnant women, breastfeeding or planning to conceive within the next year.

Following informed consent, patients would be randomised to either LCBD or low protein Diet (LPD) group.

All recruited patients will be given the standard dietary and exercise advice which will include low protein of 0.6-0.7g/kg/day and low salt diet.

In addition, patients within the LCBD will be given a prescription diet of 20g of carbohydrate daily. This will be supplemented by visual aids on carbohydrate counts of various local food. Patients would be given the option to choose their most appropriate food types which will amount to the carbohydrate count given. Patients on oral anti-diabetic treatment including insulin will advised on titrations of their medications to avoid hypoglycaemia.

The control arm will not be given any additional advice. All patients will be required to fill in a 3-day food diary during their scheduled visits which will be at 8 weeks and 16 weeks.

Clinical assessments include blood sampling of approximately 8 ml which will be done at baseline and at study end.

Studietyp

Interventionell

Inskrivning (Faktisk)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Selangor
      • Petaling Jaya, Selangor, Malaysia, 47000
        • Universiti Teknologi Mara

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  1. Diagnosed with Type 2 DM of more than 5 years
  2. Diagnosis of stable CKD of more than 6 months
  3. CKD stage 2 and 3
  4. HbA1c of 7% - 10.5%
  5. Patient age between 40-75 years old
  6. Able to sign informed consent

Exclusion Criteria

  1. Type 1 DM
  2. Frequent hypoglycaemia
  3. Persistent elevations of serum transminase
  4. Heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease
  5. Malignancy
  6. Recent hospital admission for acute within the past 3 months
  7. Pregnant women, breastfeeding or planning to conceive within the next year

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Low carbohydrate diet (LCBD)
Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
Inget ingripande: Low protein diet only (LPD)
Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline serum Creatinine at 12 weeks
Tidsram: Study end at 12 weeks
Creatinine in micromol/L
Study end at 12 weeks
Change from baseline urine microalbuminuria at 12 weeks
Tidsram: Study end at 12 weeks
Urine microalbuminuria in mmol/L
Study end at 12 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline HbA1c at 12 weeks
Tidsram: Study end at 12 weeks
HbA1c in %
Study end at 12 weeks
Change from baseline fasting plasma glucose at 12 weeks
Tidsram: Study end at 12 weeks
FPG in mmol/L
Study end at 12 weeks
Change from baseline lipid levels at 12 weeks
Tidsram: Study end at 12 weeks
Cholesterol in mmol/L
Study end at 12 weeks
Change from baseline weight at 12 weeks
Tidsram: Study end at 12 weeks
Weight in kg
Study end at 12 weeks
Change from baseline hip circumference (HC) at 12 weeks
Tidsram: Study end at 12 weeks
HC in cm
Study end at 12 weeks
Change from baseline waist circumference (WC) at 12 weeks
Tidsram: Study end at 12 weeks
WC in cm
Study end at 12 weeks
Change from baseline estimated visceral adispose tissue (Est VAT) at 12 weeks
Tidsram: Study end at 12 weeks
Est VAT in %
Study end at 12 weeks
Change from baseline blood pressure at 12 weeks
Tidsram: Study end at 12 weeks
Blood pressure in mmHg
Study end at 12 weeks
Change from baseline highly sensitivity C-reactive protein (hsCRP) at 12 weeks
Tidsram: Study end at 12 weeks
hsCRP in nmol/L
Study end at 12 weeks
Change from baseline Interleukin-6 (IL-6) at 12 weeks
Tidsram: Study end at 12 weeks
IL-6 in pg/mL
Study end at 12 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 mars 2019

Primärt slutförande (Faktisk)

5 mars 2021

Avslutad studie (Faktisk)

5 mars 2021

Studieregistreringsdatum

Först inskickad

1 juni 2021

Först inskickad som uppfyllde QC-kriterierna

10 juni 2021

Första postat (Faktisk)

18 juni 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 juni 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 juni 2021

Senast verifierad

1 juni 2021

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Unidentified subjects' raw data is required for some journal submissions

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Fetma

Kliniska prövningar på Dietary advice

3
Prenumerera